<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">Hispolon has been affirmed to possess antiproliferative activity against U87MG (glioblastoma) (
 <xref rid="bib4" ref-type="bibr">Arcella et al., 2017</xref>), HeLa, SiHa (cervical cancer) (
 <xref rid="bib39" ref-type="bibr">Hsin et al., 2017</xref>), MCF-7, MDA-MB-231 (breast carcinoma) (
 <xref rid="bib86" ref-type="bibr">Wang et al., 2017</xref>), NPC-39, HONE-1, NPC-BM, NPC-039 (nasopharyngeal cancer) (
 <xref rid="bib33" ref-type="bibr">Ho et al., 2017</xref>), A549, H661 (lung cancer) (
 <xref rid="bib89" ref-type="bibr">Wu et al., 2014</xref>), DU145, LNCaP, PC3 (prostate cancer) (49318940), MV4-11, HL-60, U937, THP-1 (leukemia) (
 <xref rid="bib36" ref-type="bibr">Hsiao et al., 2013</xref>), SGC-7901, MKN-45, MGC-803 (gastric cancer) (
 <xref rid="bib14" ref-type="bibr">Chen et al., 2008</xref>), T24, J82 (bladder cancer) (
 <xref rid="bib58" ref-type="bibr">Lu et al., 2009</xref>), Hep3B, SK-Hep1 (hepatocellular carcinoma) (
 <xref rid="bib42" ref-type="bibr">Huang et al., 2011b</xref>), TCMK-1 (renal cancer) (
 <xref rid="bib96" ref-type="bibr">Yun et al., 2019</xref>) and KB (human epidermoid) (
 <xref rid="bib13" ref-type="bibr">Chen et al., 2006</xref>) cancer cells. The anticancer efficacy of hispolon against several cancers types is shown in 
 <xref rid="fig6" ref-type="fig">Fig. 6</xref> .
</p>
